What to know about GLP-1s and heart health
The weight-loss medication Wegovy may help reduce the risk of heart attacks and strokes — here’s what the science says, who qualifies, and some notes on safety.
)
GLP-1 medications were first prescribed to treat type 2 diabetes and obesity. But then research started showing another potential benefit: that some could help reduce the risk of heart attack or stroke in high risk populations. Since then, the heart health benefits of certain GLP-1s have moved from a possibility towards something shown in clinical trials and FDA-approved. “As of now, it seems we have enough clinical trials and data to say that some GLP-1s can help reduce the risk of cardiac events,” says Dr. Nidhi Kansal, M.D., an obesity medicine specialist at Northwestern Medicine in Chicago. Not only that, the FDA has approved Wegovy for that specific purpose in qualifying patients. Keep reading to explore the science connecting certain GLP-1s and heart health, why the two are connected, and who stands to get the biggest cardiovascular benefit from their weight-loss meds.
Key takeaways
Wegovy is FDA-approved to reduce the risk of major adverse cardiovascular events, including heart attack, stroke, and cardiovascular death in adults with established heart disease and overweight or obesity.
In a large clinical trial, called SELECT, Wegovy was found to lower the risk of major cardiovascular events by 20% compared with placebo (the risk went from 8.0% to 6.5%).
Weight loss may help explain some — but not all — of the heart benefits, which include potential improvements in blood pressure, cholesterol, blood sugar, and inflammation.
Two other GLP-1 medications, Ozempic and Mounjaro, are FDA-approved to reduce major cardiovascular events in adults who have both type 2 diabetes and established heart disease.
Like any medication, GLP-1s come with the potential for side effects and may not be right for everyone.
Wegovy and cardiovascular risk
In March 2024, the FDA approved the weight-loss medication Wegovy (containing the active ingredient semaglutide) to reduce the risk of major cardiovascular events in adults who have both heart disease and either overweight or obesity. That approval was based on the SELECT clinical trial, which found that semaglutide lowered the risk of nonfatal heart attack, nonfatal stroke, and cardiovascular death in people with preexisting cardiovascular disease.
While Wegovy is the only weight-loss GLP-1 with this official heart health indication, other GLP-1s have been approved for similar purposes in other populations. Ozempic (the brand name of semaglutide approved to manage type 2 diabetes) is approved to reduce major cardiovascular events in adults who have both type 2 diabetes and heart disease. And Mounjaro (a medication for type 2 diabetes with the active ingredient tirzepatide) is approved to reduce these same events in high-risk adults with type 2 diabetes.
What the SELECT trial showed
Published in The New England Journal of Medicine in 2023, the SELECT trial included 17,604 adults ages 45 and older who had both preexisting heart disease and a body mass index (BMI) of at least 27 without diabetes. They were randomly assigned to receive weekly injections of 2.4 mg of semaglutide or a placebo, alongside standard cardiovascular care (such as their regular heart medications).
Researchers followed the participants for an average of 40 months. By the end of that time, 8% of participants taking a placebo had experienced either a heart attack or stroke or had died of cardiovascular causes, compared with 6.5% of those taking semaglutide — translating to a 20% drop in relative risk (an absolute risk reduction of 1.5%). “This is an excellent risk reduction,” notes Kansal, and it helped establish that semaglutide could improve certain heart health outcomes even in people without type 2 diabetes (something that had been determined in 2020).
Why GLP-1s help the heart (beyond weight loss)
Excess weight and heart health can be intrinsically linked. “Excess body fat possibly leads to increases in blood pressure, low-density lipoprotein (LDL) cholesterol, and other metabolic disturbances such as insulin resistance and systemic inflammation,” says Dr. Steven Heymsfield, M.D., professor at Pennington Biomedical Research Center in Baton Rouge, Louisiana, and a Weight Watchers advisory board member. “Taken together, these multiple risk factors promote coronary artery disease and stroke” (Coronary artery disease occurs when plaque narrows the arteries supplying blood to the heart; a stroke is when blood flow to part of the brain is blocked or a blood vessel ruptures.)
Losing weight safely may bolster your heart health, which is one way that GLP-1s help. “The beneficial effects [of weight loss] include lowering blood pressure and improving cholesterol and insulin-glucose metabolism — all factors leading to lowering of cardiovascular risk,” says Heymsfield. In other words, weight loss can make it easier for your heart to pump blood, reduce the buildup of plaque in your arteries, and help your body regulate blood sugar. Together, these changes can lower your risk of heart attack and stroke.
But weight loss might not tell the whole story. Researchers believe GLP-1s may also impact the heart muscle and blood vessels directly to improve their functioning, regardless of whether a person loses weight. “We don’t yet understand the direct cellular mechanism,” says Kansal, “but it may be related to inflammation.”
In a 2026 analysis of the SELECT trial data, semaglutide reduced levels of high-sensitivity C-reactive protein (hsCRP), a marker of systemic inflammation, by nearly 38% over the course of two years. But that reduction actually appeared early on, within the first month or two, before participants had lost much weight. And it was also seen in participants who didn't lose weight, suggesting that the anti-inflammatory effect of the medication could be directly contributing to its heart health benefits.
Who is this for?
People who are eligible to take Wegovy for cardiovascular-risk reduction are adults who have both established cardiovascular disease and either overweight or obesity (to be specific: having a BMI of 27 or over). Established cardiovascular disease means a person already has certain forms of heart or blood-vessel disease, such as having had a prior heart attack or stroke. A clinician can determine whether someone’s medical history meets the criteria.
If you have obesity (BMI 30 or higher) or overweight (BMI 27 or higher with at least one weight-related comorbid condition) without established cardiovascular disease, you may still qualify to take Wegovy for chronic weight management, just not specifically to reduce your risk of heart events. Wegovy is also not approved for people who may have an increased risk of cardiovascular disease due to conditions such as genetics, high cholesterol, and hypertension but who are not overweight. “If someone has a BMI of 23 and no prior heart disease but is worried about their future risk because of their family history, Wegovy is still not the appropriate prevention for this patient,” says Kansal.
People with type 2 diabetes may qualify for a different GLP-1 that may improve their blood sugar management and, in certain cases, cardiovascular health. Adults with both established heart disease and type 2 diabetes may meet the criteria for Ozempic’s heart health benefit, while Mounjaro’s approval applies to adults with type 2 diabetes who are at high risk for major cardiovascular events. Your healthcare provider can review your medical history, current medications, risk factors, and treatment goals to help determine which medication options, if any, are right for you.
Side effects, warnings, and who shouldn’t take it
Wegovy and other prescribed weight-loss medications carry a risk of potential side effects, particularly as the dose increases. Common GLP-1 side effects include nausea, diarrhea, vomiting, constipation, and abdominal pain. Some people experience more serious gastrointestinal problems, such as gastroparesis (where the stomach takes longer than expected to empty food) or intestinal blockage. Other potential risks include pancreatitis, gallbladder problems, hypoglycemia (low blood sugar), and kidney injury associated with dehydration.
There is another concern to know about: GLP-1s carry an FDA boxed warning regarding the risk of thyroid C-cell tumors. In rodent studies, semaglutide caused thyroid C-cell tumors; it is unknown whether it causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. People with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2) must not take them.
GLP-1 medications aren’t a substitute for other cardiovascular treatments. If you take medication for blood pressure, cholesterol, diabetes, or other heart-related conditions, don’t stop taking it or change doses on your own just because you’ve started taking Wegovy or another GLP-1. That said, losing weight could potentially help you need less of certain heart-related meds in the long run. “It’s not uncommon that a patient’s needs for blood pressure and diabetes medicines are altered with the improved cardiovascular and metabolic state accompanying GLP-1 treatment,” says Heymsfield. Your healthcare provider can monitor your heart risk factors like cholesterol and blood pressure and determine whether you might be able to reduce your medications for those conditions as your weight health improves.
Find a full list of Wegovy’s side effects in the package insert.
How Weight Watchers supports heart-healthy weight management
Weight Watchers Med+ connects members who medically qualify with clinicians who can prescribe FDA-approved GLP-1s like Wegovy for chronic weight management. (They are unable to prescribe them for cardiovascular disease prevention.) It’s also important to note that medication is only one part of managing weight for long-term heart health — food choices, physical activity, and building sustainable habits matter — which is why all Med+ members get access to the GLP-1 Success Program. You’ll get the nutrition and behavior-change support needed to improve your overall wellness while losing weight, including coaching, on-demand workouts, an app for tracking food, activity, and progress, access to 12,000+ recipes, and a community platform where you can connect with fellow GLP-1 members who are focused on their health.
After 6 months of the Med+ GLP-1 Success Program, members with hypertension reduced their systolic blood pressure by 11% and diastolic blood pressure by 9%, on average.*
The bottom line
The health benefits of GLP-1s extend beyond weight loss alone. Wegovy, in particular, can also lower the risk of heart attack and stroke in people with existing heart disease and overweight or obesity. Some of that protection likely comes from weight loss itself, which can improve blood pressure, cholesterol, and blood sugar. But GLP-1s also potentially reduce inflammation — making them a powerful multiplier for the heart-healthy habits that have always been the focus of Weight Watchers programs.